Skip to main content
News Icon

News categories: Publication

Tumor microenvironment of Pancreatic Cancer

Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells

While studying B cells in pancreatic cancer, we noticed an important discrepancy between human data, which suggest B cells contribute to the anti-tumor response, and mouse data, which indicate an immunosuppressive, protumorigenic role. Most of the murine data, however, derives from orthotopic models, in which a pancreatic-cell line is injected in the pancreas of healthy mice and tumors develop rapidly. In order to clarify this discrepancy, we assessed B-cell infiltrates from orthotopics and a genetic mouse model, the KPC mouse, in which tumors develop spontaneously in the course of several months, due to overexpression of mutated KRAS and P53 in pancreatic cells. Our data showed that orthotopic tumors have no immune-cell infiltrate, while KPC tumors do, better mimicking human cancers. Furthermore, infiltrating B cells present a very different phenotype from B cells residing in the spleen and lymph-nodes, showing signs of activation and differentiation, as well as expression of immune-stimulatory factors. Indeed, depletion of B cells with anti-CD20 treatment in KPC mice, did not cause a decrease in tumor growth. As B-cell infiltration correlated with T-cell and DC infiltration, we hypothesize that B cells infiltrating pancreatic tumors contribute to the adaptive anti-tumor response and therefore have tumor suppressing roles. However, B cells residing in secondary lymphoid organs have a different, possibly more immunosuppressive phenotype. Our results indicate that strategies to increase tumor infiltration by immune cells could be beneficial in the treatment of this dismal disease.


Publication

https://pubmed.ncbi.nlm.nih.gov/30972056/


Contact

Dr. Melania Capasso

DZNE

Related news

Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

News categories: Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

News categories: Publication

A Ray of Hope in the Fight Against Cancer

Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry
(from left) Julia Nicke and Dr. Mona Malek Mohammadi have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury.

News categories: Publication

Central Hub for Heart Repair Discovered Bonn study: Heart muscle interaction enables cardiac regeneration in the neonatal heart

Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).
View entry

Back to the news overview